New immune therapy targets brain cancer in early trial
NCT ID NCT06922604
Summary
This early-stage study is testing the safety and side effects of a new two-part drug treatment for lymphoma that has spread to the brain or spinal cord. The treatment involves an antibody called glofitamab, which is designed to help the body's own immune cells find and attack the cancer. Researchers will enroll about 20 adults who have not responded to standard treatments to see if this approach is safe and shows signs of working.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.